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Cardiac contractility is mediated by a variable flux in
intracellular calcium (Ca2+), thought to be integrated
into mitochondria via the mitochondrial calcium uni-
porter (MCU) channel to match energetic demand.
Here, we examine a conditional, cardiomyocyte-spe-
cific, mutant mouse lacking Mcu, the pore-forming
subunit of the MCU channel, in adulthood. Mcu/
mice display no overt baseline phenotype and are
protected against mCa
2+ overload in an in vivo
myocardial ischemia-reperfusion injury model by
preventing the activation of the mitochondrial
permeability transition pore, decreasing infarct size,
and preserving cardiac function. In addition, we
find that Mcu/ mice lack contractile responsive-
ness to acute b-adrenergic receptor stimulation
and in parallel are unable to activate mitochondrial
dehydrogenases and display reduced bioenergetic
reserve capacity. These results support the hypothe-
sis that MCU may be dispensable for homeostatic
cardiac function but required to modulate Ca2+-
dependent metabolism during acute stress.INTRODUCTION
The cardiomyocyte is unique in that a large and variable flux of
intracellular calcium (iCa
+2) must occur to mediate and regulate
contraction. Thus, a complex system has evolved to regulate
iCa
2+ transport to maintain homeostatic conditions (Bers, 2008).
Numerous genetic components have been shown to mediate
the passage of iCa
2+ across the sarcolemma and sarcoplasmic
reticulum (SR), and, while great strides have been made toward
understanding the temporal and spatial relationship of Ca2+ in re-
gards to excitation-contraction (EC) coupling, our understanding
of other sub-cellular Ca2+ domains, including the components of
mitochondria Ca2+ (mCa
2+) exchange, remains elementary.The dynamic Ca2+ environment of the heart requires that
cardiac mitochondria possess an exchange system capable
of dealing with the variable changes in Ca2+ load. Ca2+ enters
the mitochondrial matrix via the mitochondria calcium uniporter
(MCU). The MCU is an inward rectifying, low-affinity, high-
capacity channel whose uptake is mediated by mitochondrial
membrane potential (Dc = approximately –180 mV) generated
by the electron transport chain (ETC) (Kirichok et al., 2004).
The recent identification of the gene encoding the channel-
forming portion of the uniporter, formerly named CCDC109A
now known as MCU, has opened the field to genetic gain-
and loss-of-function studies to determine experimentally the
true role of mCa
2+ signaling in the regulation of numerous pro-
posed cellular processes (Baughman et al., 2011; De Stefani
et al., 2011). To date, multiple reports have confirmed MCU
as being required for acute mCa
2+ influx into the matrix. How-
ever, numerous outstanding questions remain in regards to
the molecular regulation of the MCU and the physiological
function of mCa
2+, particularly in excitable cells such as
cardiomyocytes.
The high metabolic demand of contractility makes it essential
that an efficient and tightly controlled system be in place to regu-
late energy production. Oxidative Phosphorylation (OxPhos) is
the largest contributor to myocardial metabolism and as such
the mitochondria represents a central control point to ensure
that energy demands are met. Simultaneous measurements of
mCa
2+ and NADH have correlated increased mCa
2+ load with
increased oxidative phosphorylation and ATP production
(Brandes and Bers, 2002; Unitt et al., 1989). Thus, Ca2+ is pro-
posed to be the link between EC coupling (ECC) and OxPhos
and has been shown to modulate mitochondrial metabolism
through numerous mechanisms including the activation of
Ca2+-dependent dehydrogenases and modulation of ETC com-
plexes (Glancy and Balaban, 2012).
In contrast to the aforementioned pro-survival metabolic
signaling, numerous studies have implicated mCa
2+ overload in
the activation of apoptosis and necrosis (Rasola and Bernardi,
2011). mCa
2+ is known to cause outer-mitochondrial membrane
(OMM) permeability prompting the release of apoptogens. Ca2+
is also thought to be themajor priming event in the opening of theCell Reports 12, 23–34, July 7, 2015 ª2015 The Authors 23
mitochondrial permeability transition pore (MPTP) causing the
collapse of Dc and loss of ATP production resulting in necrotic
cell death. This mechanism of cellular demise is believed to
significantly contribute to the initiation and progression of
myocardial infarction and heart failure (Foo et al., 2005). In addi-
tion, it has been speculated that mitochondria in close contact to
the sarcoplasmic reticulum (SR) may buffer iCa
2+ cycling and
thereby play a direct role in modulating EC coupling, providing
yet another layer of potential regulation (Drago et al., 2012; Riz-
zuto et al., 1998).
To begin to unravel how mCa
2+ signaling modulates in vivo
physiology, a group at the NHLBI recently generated a Mcu
gene-trap mouse (Pan et al., 2013). As expected, mitochondria
isolated from this global Mcu-null mouse failed to take up
Ca2+. However, while they did find alterations in some aspects
of skeletal muscle work capacity, they did not find a significant
cardiac phenotype. Particularly intriguing, they found no change
in myocardial infarct size in an ex vivo global ischemia model
even though in vitro indices of MPTP opening appeared to be
completely absent. These surprising results have spurred the
field to question the true role of mCa
2+ signaling in the normal
and diseased heart.
To advance our understanding of mCa
2+ uptake in the heart, in
collaboration with the Molkentin lab, we generated a conditional,
loss-of-function mouse model (Mcufl/fl) and coupled with a
tamoxifen-inducible, cardiomyocyte-specific Cre recombinase
transgenic line, deleted Mcu in adulthood (Kwong et al., 2015
[this issue of Cell Reports]). Here, we report that loss ofMcu ab-
lates mCa
2+ uptake and activity (IMCU) and protects against cell
death in an in vivo ischemia-reperfusion (IR) injury model by pre-
venting the activation of themitochondrial permeability transition
pore (MPTP). In addition, we found that Mcu-null mice lacked
in vivo contractile responsiveness to b-adrenergic receptor
(bAR) stimulation and in parallel were unable to activate mito-
chondrial dehydrogenases and meet energetic demand. Further
experimental analysis confirmed a lack of energetic responsive-
ness to acute sympathetic stress, supporting the hypothesis that
the physiological function of the MCU is to match Ca2+-depen-
dent contractile demands with mitochondrial metabolism during
the ‘‘fight-or-flight’’ response.
RESULTS
Generation of aMcuConditional KnockoutMouseModel
and Validation of Functionality
TheMcu targeting construct was designed with loxP sites flank-
ing the critical exons 5–6, which encode the DIME motif, an
evolutionarily conserved sequence hypothesized to be neces-
sary for Ca2+ transport (Bick et al., 2012; Kwong et al., 2015,
this issue). Three independent mutant ES cell lines were
confirmed and subjected tomorula aggregation and subsequent
embryos transplanted into pseudo-pregnant females. Two of the
threemutant ES cell lines produced germlinemutantmice, which
were crossed with ROSA26-FLPe mice for removal of the FRT-
flanked neomycin cassette (Figure 1A). Cre-mediated deletion
of exons 5–6 results in a frameshift and early termination of trans-
lation causing complete loss of MCU protein in all cells express-
ing Cre recombinase. Homozygous ‘‘floxed’’ mice (Mcufl/fl) were24 Cell Reports 12, 23–34, July 7, 2015 ª2015 The Authorsinterbred, and mouse embryonic fibroblasts (MEFs) were iso-
lated from E13.5 embryos. MEFs were infected with adenovirus
expressing Cre recombinase (Ad-Cre) or bgal control virus and
cells were lysed for western blot analysis of MCU protein expres-
sion 6 days later. Ad-Cre treatment resulted in a dose-dependent
loss of MCU (Figure 1B). COXIV was used as a mitochondrial
loading control. (Expression of additional mCa
2+ exchange
associated proteins can be seen in (Figure S1A). ETC complex
expression served as a mito loading control (Figure S1B).
Mcufl/fl Ad-Cre or Ad-bgal treated MEFs were subsequently in-
fected with AAV-mitycam (mito-targeted genetic Ca2+ sensor)
and cells imaged 48 hr later to monitor mCa
2+ exchange. ATP
treatment (purinergic, IP3-mediatedCa2+ release) elicited a rapid
decrease in mitycam fluorescent signal inMcufl/fl Ad-bgal MEFs
(mitycam is an inverse reporter, data shown as 1-F/F0). Cells
treated with Ad-Cre displayed almost complete loss of the acute
mCa
2+ transient (Figure 1C). This difference was not attributable
to a decrease in the iCa
2+ transient (Figure S1C). Quantification
of mitycam amplitude immediately following ATP treatment
found an 75% decrease in mCa2+ (Figure 1D). It should be
noted that we did consistently observe that Mcu-KO MEFs
continued to slowly take up Ca2+ and eventually reached levels
equivalent to control cells. Next, Mcufl/fl Ad-Cre- or Ad-bgal-in-
fected MEFs were examined for mCa
2+ uptake capacity by
loading digitonin permeabilized cells with the Ca2+ sensor,
Fura-FF, and the membrane potential sensitive dye, JC-1 for
simultaneous ratiometric recording. Cells were treated with
thapsigargin to inhibit SERCA and block ER Ca2+ uptake.
Upon reaching a steady-state membrane potential, cells were
exposed to seven consecutive pulses of 5 mM Ca2+ (Figures 1E
and 1F). A decrease in Fura signal after each bolus of bath
Ca2+ represents mCa
2+ uptake. Quantitative analysis after expo-
sure to 10 mMCa2+ (a concentration whereMCU is fully activated
in non-excitable cells) revealed Mcu-null MEFs to have a near
complete loss of mCa
2+ uptake compared to control MEFs (Fig-
ure 1G). Analysis ofDc revealed no difference between groups at
baseline or after delivery of 10 mMCa2+, confirming the observed
change in uptake was not a result of an alteration in the driving
force for mCa
2+ uptake (Figure 1H). Incremental increases in
mCa
2+ eventually led to a decrease in membrane potential in
bgal control MEFs, a phenomenon not observed in Mcu-null
MEFs even after substantial Ca2+ challenge (Figure 1I). It should
be noted that in an attempt to make a MEF Mcu/ cell line, we
crossed Mcufl/fl mice with a transgenic germline-Cre model
(B6.CMV-Cre, JAX Mice) to generate Mcu+/ for subsequent
interbreeding. However, heterozygous mating (more than six
litters) failed to yield Mcu/ pups, suggesting homozygous
deletion results in embryonic lethality.
Genetic Deletion of Mcu Results in the Complete Loss
of Uniporter Ca2+ Uptake in ACMs
Mcufl/fl mice were crossed with the well-characterized aMHC-
Cre transgenic mouse model to yield cardiomyocyte-specific
loss ofMcu (Figure 2A). Adult cardiomyocytes (ACMs) were iso-
lated from wild-type (WT), aMHC-Cre, Mcufl/fl, and Mcufl/fl 3
aMHC-Cremice at 8–12 weeks of age. Western blot assessment
found an 80% reduction in MCU protein compared to all con-
trols; in accordance with previous reports of the mosaicism of
Figure 1. Generation of a Conditional Mcu Knockout Mouse Model and Confirmation of Functionality
(A) Schematic of Mcu targeting construct. LoxP sites (red triangles) flank exons 5–6. A neomycin (Neo) selection cassette is flanked by FRT sites (green half-
circles). Mutant mice were crossed with ROSA26-FLPe mice for removal of Neo. Floxed mice (conditional allele) were crossed with cardiomyocyte-specific Cre
recombinase driver lines resulting in deletion of Mcu.
(B) Mouse embryonic fibroblasts (MEFs) were isolated fromMcufl/flmice at E13.5. MEFs were infected with adenovirus expressing Cre recombinase (Ad-Cre) or
the experimental control b-galactosidase (Ad-bgal). 6 days post-infection with Ad-Cre, cells were lysed and MCU protein expression was examined by western
blot. COXIV was used as a mitochondrial loading control.
(C)Mcufl/fl MEFs were treated with Ad-Cre or Ad-bgal and subsequently infected with Adeno encoding mitycam, mCa
2+ sensor, 48 hr prior to imaging. Baseline
was recorded, and a single pulse of 1 mM ATP was delivered to liberate iCa
2+ stores.
(D) Signal means shown as solid lines with dashed lines displaying ± SEM mCa
2+ amplitude (peak intensity immediately after ATP – baseline).
(E)Mcufl/flMEFswere treated with Ad-bgal and loaded with the Ca2+ sensor (Fura-FF), and theDc sensor (JC-1) was permeabilized with digitonin and treated with
thapsigargin (SERCA inhibitor) for simultaneous ratiometric monitoring during repetitive additions of 5 mM Ca2+ (blue arrows). FCCP was used as a control to
collapse Dc at the conclusion of each experiment.
(F) Mcufl/fl MEFs were treated with Ad-Cre and subjected to identical experimental conditions.
(G) Percentage of mCa
2+ uptake versus Ad-bgal control cells following 10 mM Ca2+ (second pulse).
(H) JC-1-derived Dc prior to Ca2+ additions.
(I) JC-1-derived Dc following seven pulses of 5 mM Ca2+.
All data shown as mean ± SEM, ***p<0.001 vs. bgal control.the aMHC-Cre transgenic strain (Figure 2B) (Oka et al., 2006).
No expression changes in ETC complex subunits were found
(Figure S2A). To examine baseline mCa
2+ content, ACMs were
loaded with the ratiometric Ca2+ reporter, Fura-2, and treated
with Ru360 (MCU inhibitor), CGP37157 (mNCX inhibitor), thapsi-
gargin (SERCA inhibitor) and permeabilized with digitonin to
block all Ca2+ flux. During spectrofluorometric recording the
protonophore, FCCP, was injected to dissipate Dc allowing
the release of all matrix free-Ca2+ (Figure 2C). Quantification of
these data by calibration of the Fura-2 reporter in our experi-
mental system (Figure S2B) found no change in matrix Ca2+ con-
tent in Mcu knockout (KO) ACMs (Figure 2D). Next, mCa
2+ up-
take capacity was evaluated in ACMs isolated from bothMcufl/fl and Mcufl/fl 3 aMHC-Cre mice (Figures 2E and 2F).
The simultaneous recording of mCa
2+ uptake andmembrane po-
tential discovered that Mcu KO ACMs were completely refrac-
tory from high Ca2+ challenge and failed to take up Ca2+, quan-
tified after the second 10 mM Ca2+ pulse (Figure 2G). Mcufl/fl 3
aMHC-Cre ACMs displayed a slightly higher baseline mitochon-
drial membrane potential, although not reaching statistical
significance, confirming that the lack of Ca2+ uptake was not
due to a decrease in Dc (Figure 2H). Further, Mcu-null ACMs
were entirely resistant to Ca2+-overload loss of Dc as observed
in control cells. In fact, nine repeated boluses of 10 mM Ca2+
failed to elicit mitochondrial depolarization in Mcu KO ACMs
(Figure 2I).Cell Reports 12, 23–34, July 7, 2015 ª2015 The Authors 25
Figure 2. Biophysical Characterization of Mcu KO ACMs
(A) Mcufl/fl mice were crossed with aMHC-Cre mice, and ACMs were isolated from hearts of adult mice.
(B) ACMs were isolated from wild-type (WT), aMHC-Cre (Cre), Mcufl/fl, and Mcufl/fl 3 Cre. Samples were lysed and immunoblotted for MCU protein expression
and the mitochondrial loading control COXIV.
(C) ACMs were loaded with the Ca2+ sensor Fura-2. The sarcolemma was permeabilized with digitonin in the presence of thapsigargin (SERCA inhibitor), CGP-
37157 (mNCX inhibitor), and Ru360 (MCU inhibitor). Ca2+ levels were recorded and, upon reaching a stable baseline, free-mCa
2+ was released from the mito-
chondrial matrix with FCCP.
(D) Quantification of matrix Ca2+ content after Fura calibration.
(E and F)Mcufl/fl or Mcufl/fl3 aMHC-Cre ACMswere loadedwith the Ca2+ sensor (Fura-FF), and theDc sensor (JC-1) was permeabilized with digitonin and treated
with thapsigargin (SERCA inhibitor) for simultaneous ratiometric monitoring during repetitive additions of 10 mMCa2+ (blue arrows). FCCPwas used as a control to
collapse Dc at the conclusion of each experiment.
(G) Percentage of mCa
2+ uptake versus Mcufl/fl following the addition of 20 mM Ca2+.
(H and I) JC-1 quantified Dc at baseline and post-Ca2+ pulses.
(J) Mitochondria were isolated from ACMs, and mitoplasts were prepared to record MCU current (iMCU). Data are reported as mean current recordings; the
voltage ramping protocol is above in gray shaded area.
(K) Current density measured in picoamperes per picofarad (pA/pF).
(L) Current-time integral measurements, femtomole per picofarad (fmol/pF).
Minimum of three independent experiments for all quantified data; all data shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.To confirm that deletion of theMcu gene results in loss ofMCU
channel activity (IMCU), we isolated ACMs, generated mitoplasts,
and employed the whole-mitoplast voltage-clamping technique
developed by the Clapham group that first established the uni-
porter as the prototypical uptake channel (Kirichok et al.,
2004). IMCU was absent in Mcu-null mitoplasts subjected to a
ramping protocol from 160 mV to 80 mV (Figure 2J). Quantita-
tive analysis revealed a decrease in current density (Figure 2K),
and likewise the current-time integral (area under the curve)
was minimal (Figure 2L). These data are in agreement with initial26 Cell Reports 12, 23–34, July 7, 2015 ª2015 The Authorsand subsequent reports of MCU channel biophysical activity
(Chaudhuri et al., 2013; Fieni et al., 2012; Kirichok et al., 2004).
Collectively, these experiments corroborate that Mcu is neces-
sary for rapid mCa
2+ uptake in cardiomyocytes.
MCU-Mediated mCa
2+ Uptake Is a Significant
Contributor to Myocardial IR Injury
Given the well-substantiated role of Ca2+ in activating the MPTP
and the numerous reports that MPTP inhibition is a potent ther-
apeutic strategy to reduce necrotic cell death (Rasola and
Figure 3. Genetic Ablation of Mcu Protects
against Myocardial IR Injury
(A) Mcufl/fl, aMHC-Mer-Cre-Mer (aMHC MCM),
and Mcufl/fl 3 aMHC-Mer-Cre-Mer mice were
treated with tamoxifen (40mg/kg/day) for 5 days to
induce cardiomyocyte-restricted Cre expression
and allowed to rest for 3 weeks prior to 40 min of
ischemia and 24-hr reperfusion.
(B) Representativemid-ventricular cross sections of
TTC-stainedhearts. (Evan’s-blue-stainedarea,non-
ischemic zone; remaining area, area-at-risk; white
area, infracted tissue; red area, viablemyocardium.)
(C)Planimetery analysis of infarct sizebyquantifying
Evan’s blue dye excluded area, area-at-risk (AAR),
left ventricle (LV) area, and non-TTC-stained area =
infarct (INF).
(D) 24 hr after reperfusion, serumwas collected, and
cardiac troponin-I (cTnI) was measured by ELISA.
(E–G) Mice were analyzed by echocardiography,
and measurements of LV end-diastolic diameter
(LVEDD), LV end-systolic diameter (LVESD), and
percentage of fractional shortening (FS%) were
acquired.
(H) Mitochondria were isolated from hearts of adult
mice, and changes in swelling (decreased absor-
bance at 540 nm = increase in volume) were
assessed ±2 mM CsA. Swelling was initiated by in-
jection of 500 mMCa2+.
(I) Changes in swelling quantified by measuring the area under the curve (AUC) and correcting to control.
All in vivo experiments minimum of n = 7 for all groups; data shown as mean ± SEM, *p < 0.05, **p < 0.01.Bernardi, 2011), we next assessed genetic loss of Mcu in an
in vivo model of myocardial IR injury.Mcufl/fl, aMHC-MerCreMer
(MCM), and Mcufl/fl 3 aMHC-MCM (Mcu cKO) mice (aged 10–
12 weeks) were all injected intraperitoneally (i.p.) for 5 consecu-
tive days with 40 mg/kg tamoxifen (see Figures S3A and S3B for
mCa
2+ exchange associated proteins and ETC complex expres-
sion post-tamoxifen) and 3weeks later subjected to left coronary
artery (LCA) ligation for 40-min and 24-hr reperfusion (Figure 3A).
The evaluation of left ventricle (LV) infarct size by TTC staining
and Evan’s blue dye perfusion revealed Mcu cKO mice to have
an 45% reduction in infarct size (INF) per area at risk (AAR)
versus controls; AAR was similar between all groups (Figures
3B and 3C). To corroborate this result, serum from the same
cohort of mice was collected 24 hr after reperfusion, and a car-
diac troponin-I (cTnI) ELISA was performed as a secondary
marker of cardiomyocyte cell death. Mcu-deleted mice dis-
played an 65% reduction in cTnI versus controls (Figure 3D).
We also examined DNA fragmentation by TUNEL staining, to
demarcate cell death. We found a significant reduction in
TUNEL+ nuclei in the infarct boarder zone of Mcu cKO hearts
as compared to controls (Figures S3C and S3D).
Echocardiographic assessment of LV function 24 hr post-IR
revealed a significant preservation of LV end-systolic diameter
(LVESD) and percentage of fractional shortening (FS%) in Mcu
knockout mice (Figures 3E–3G). Additional M-mode echocardio-
graphic data can be seen in Table S1. To account for differences
in regional wall motion due to variances in infarct size, we utilized
speckle-tracking of B-mode echocardiographic recordings and
likewise found an improvement in LV function in Mcu cKO
mice post-IR (Figures S3E–S3I).To further examine the resistance of Mcu-null cardiomyo-
cytes to mitochondrial depolarization during Ca2+ overload as
reported above in Figure 2I, we next isolated mitochondria
from hearts and employed the classical mitochondrial-swelling
assay to examine MPTP opening. Mitochondria isolated from
Mcu-KO hearts failed to swell in response to increasing bath
Ca2+, signified by a decrease in absorbance, in striking contrast
to control mitochondria (Figure 3H, red versus black line). For
these experiments, we utilized a substantial Ca2+ bolus
(500 mM), such that the CypD inhibitor cyclosporine A (CsA)
only had a partial inhibitory effect on swelling (gray line) in com-
parison to Mcu deletion. These data are quantified in Figure 3I
as percentage of change in area under the curve versus control.
It has previously been reported that MPTP opening occurs inde-
pendent of CypD at high Ca2+ loads similar to those utilized
here (Baines et al., 2005). To account for possible compensa-
tory alterations in the expression of MPTP components, we im-
munoblotted for CypD, ANT, and VDAC (Figure S3J). We found
no differences in expression between Mcu cKO and control
hearts. These results support the hypothesis that the loss of
Mcu prevents Ca2+ from entering the matrix and activating the
MPTP and thereby reduces IR-mediated cardiomyocyte cell
death.
mCa
2+ Uptake Is Necessary to Match Energetic Supply
with b-Adrenergic Contractile Demand
Numerous studies have suggested that ECC Ca2+ cycling is in-
tegrated into mitochondria to match ATP production with work-
load (Williams et al., 2015). Given that we did not find a signifi-
cant difference in baseline cardiac function or resting mCa
2+Cell Reports 12, 23–34, July 7, 2015 ª2015 The Authors 27
Figure 4. mCa
2+ Uptake Is Required for
b-Adrenergic-Mediated Increases inContrac-
tility and Bioenergetic Responsiveness
(A) Mice in all groups received tamoxifen (40 mg/kg/
day) for 5 days and 1week later were subjected to an
isoproterenol (Iso) infusion protocol (0.1–10 ng/ml)
over 15 min.
(B–D) Invasive hemodynamic analysis of dp/dtmax,
dp/dtmin, and heart rate (HR) during Iso infusion
(minimum n = 7/group).
(E) Baseline expression analysis of pyruvate dehy-
drogenase (PDH) phosphorylation at S293 of the E1a
subunit and total PDH expression (subunits E2,
E3bp, E1a, E1b). ETCComplexV-subunit dwas used
as a loading control.
(F) Hearts were freeze-clamped at the conclusion of
Iso infusion protocol and western blot examination
of PDH phosphorylation at S293 of the E1a subunit,
and total PDH expression (subunits E2, E3bp, E1a,
E1b) was performed.
(G) Fold change in PDH phosphorylation versus
control. Band density analysis was calculated as
p-PDHS293/total PDH (E1a).
(H) PDH activity of samples from hearts during Iso
administration, expressed asmOD/min/mg of tissue.
(I) Cardiac NAD+/NADH ratio following Iso infusion;
datawere expressed as fold change versus baseline.
All data shown asmean± SEM, *p < 0.05, **p < 0.01,
***p < 0.001.content, we next induced acute cardiac stress using an adren-
ergic agonist to elevate the iCa
2+ load in an attempt to unmask
the physiological function of the MCU. Mcufl/fl, aMHC-MCM,
and Mcu cKO mice were injected i.p. for 5 consecutive days
with 40 mg/kg tamoxifen, and 10 days later we measured LV
hemodynamic parameters during intravenous (i.v.) infusion of
isoproterenol (Iso) (Figure 4A). Mcu cKO mice failed to increase
LV contractility (dp/dt max) in response to b-adrenergic stimu-
lation as compared to control mice (Figure 4B). In addition,
there was a noted, although less dramatic, impairment in LV
relaxation (dp/dt min, Figure 4C). There was no significant dif-
ference in heart rate (HR) between groups over the course of
Iso infusion (Figure 4D).
Following 10 min of Iso infusion, we snap-froze ventricular tis-
sue for metabolic analysis. We first evaluated the status of the
pyruvate dehydrogenase complex (PDH), the prototypical
mCa
2+-dependent enzyme that converts pyruvate into acetyl-
CoA for use in the tricarboxylic acid (TCA) cycle. PDH is a central
component linking glycolysis to OxPhos and also a contributor to
the NADH pool. mCa
2+ is reported to increase PDH phosphatase
activity (PDP1), which, in turn, dephosphorylates the S293 resi-
due on the E1 subunit resulting in increased PDH enzymatic ac-
tivity. There was no change in the baseline expression of phos-
pho-PDH, total PDH complex (Figure 4E), or other proposed
mCa
2+-regulated dehydrogenases (a-ketoglutarate dehydroge-
nase and isocitrate dehydrogenase; Figure S4A). However,
expression analysis of post-Iso samples revealed a substantial
decrease in phosphorylation of S293-E1 in control hearts versus
Mcu cKO samples (Figure 4F, top panel). There was no change in
total protein expression for any of the PDH subunits post-Iso
(Figure 4F, bottom panel). Quantification of phospho/total28 Cell Reports 12, 23–34, July 7, 2015 ª2015 The AuthorsE1-PDH revealed Mcu-KO hearts to have greater than a 3-fold
difference in phosphorylation versus controls, signifying a failure
to activate PDH during adrenergic stimulation (Figure 4G). This
result was confirmed by our observation of an 50% decrease
in Iso-stimulated PDH enzymatic activity inMcu cKO hearts (Fig-
ures 4H and S4B). To examine baseline energetics in more detail
and rule out any compensatory changes in ourMcu cKO model,
we employed metabolomics to measure the levels of several
prominent TCA intermediates (Figures S4C and S4D). Mass
spectrometry of ventricular tissue found no difference in any of
the metabolites assayed.
Next, wemeasured theNAD+/NADH ratio, and, while we found
no difference at baseline, acute Iso stimulation revealed an 2-
fold difference in Mcu cKO hearts versus controls (Figure 4I).
We also examined the NADP+/NADPH ratio and again found
no difference at baseline but did find a trend of increased
NADP+/NADPH ratio in Mcu cKO hearts during Iso infusion
(Figure S4E). This was somewhat surprising since we thought
NADPH generation was primarily extra-mitochondrial via the
pentose phosphate pathway. However, mitochondrial enzymes
such as malic enzyme, NADP-linked isocitrate dehydrogenase,
and mitochondrial methylenetetrahydrofolate dehydrogenase
are other significant sources of NADPH production (Fan et al.,
2014; Huang and Colman, 2005; Palmieri et al., 2015; Yang
et al., 1996). It is intriguing to think that this may be another meta-
bolic consequence of altering the mCa
2+microdomain during
stress, be it direct or indirect modulation.
To further examine the hypothesis that MCU-Ca2+ uptake is
necessary to increasemyocardial energy production in response
to acute sympathetic signaling, we employed a cellular system to
monitor energetic changes in real-time. ACMs were isolated
Figure 5. Mcu Is Necessary for b-Adrenergic
Increases in Mitochondrial Energetics
ACMs were isolated from Mcufl/fl and Mcufl/fl 3
aMHC-MCM hearts 1 week post-tamoxifen treat-
ment.
(A) ACMs were monitored spectrofluorometrically
for changes in NADH autoflourescence after treat-
ment with isoproterenol (Iso, 10 mM) followed by the
addition of rotenone (Rot, 2 mM). Mean NADH
recording from three independent experiments.
(B) Baseline NADH levels calculated as fluorescent
intensity.
(C) Percentage of change in NADH levels following
Iso treatment, corrected to Mcufl/fl ACMs.
(D) NADH fluorescent intensity after treatment with
rotenone, calculated as percentage of change from
baseline to post-rotenone corrected to control
ACMs.
(E) Isolated ACMs were assayed for mitochondrial
OxPhos function using a Seahorse Bioanalyzer to
measure the baseline oxygen consumption rate
(OCR).
(F) ACMs were treated with either vehicle (Veh) or
isoproterenol (Iso, 10 mM), and FCCP was injected
to augment maximal OCR.
All data shownasmean±SEM, *p<0.05, ***p<0.001
versus Mcufl/fl; ##p < 0.01, ###p < 0.001 versus Veh.from Mcufl/fl and Mcufl/fl 3 aMHC-MCM mice 10 days after
administration of tamoxifen. We first monitored iCa
2+ transients
at both baseline and during Iso delivery to rule out the possibility
of decreased bAR responsiveness in our Mcu cKO cells (Fig-
ure S5). We found Mcu cKO ACMs to have no impairment in
Iso-mediated augmentation of iCa
2+ signaling during pacing.
Next, ACMs were monitored for changes in NADH autofluores-
cence intensity (Figure 5A). While we found no difference in basal
NADH levels between groups (Figure 5B), the administration of
Iso (10 mM) elicited a significant increase in NADH production
in control ACMs, while Mcu-KO myocytes were unresponsive
with NADH consumption being greater than production. Quanti-
fication of these data with correction to control ACMs can be
seen in Figure 5C. To examine maximal NADH production in
the presence of Iso, we next inhibited complex I of the ETC
(NADH dehydrogenase) with rotenone. Mcu-KO ACMs dis-
played an 50% reduction in maximal NADH production, as
compared to control (Figure 5D). To evaluate whether the lack
of NADH responsiveness correlated with an alteration in OxPhos
capacity, we measured ACM oxygen consumption rates (OCR)
using a Seahorse extracellular flux analyzer. Corroborating our
previous data showing no change in baseline NADH, there was
no difference in baseline respiration between groups (Figure 5E).
Next, we examined maximal respiratory capacity (maxOCR,Cell Reports 12,FCCP treatment) in the presence of Iso
or vehicle (veh).Mcu-null ACMs displayed
a significant reduction in maxOCR, as
compared to controls, and were
completely refractory to Iso-mediated in-
creases in mitochondrial respiration (Fig-
ure 5F). In summation, these results sup-port the concept of metabolic failure due to an inability to
increase reducing equivalents during acute stress.
DISCUSSION
Since the 1970s, it has been apparent that mitochondria con-
tained a protein capable of inducing an inward rectifying Ca2+
current (Sottocasa et al., 1972). The subsequent identification
of a pharmacological inhibitor, of the channel, ruthenium red
(RR), allowed investigators to begin to probe the cellular function
of mCa
2+ exchange (Moore, 1971). Various studies employing RR
or a derivative have implicated mCa
2+ in numerous cellular pro-
cesses, most notably the regulation of metabolism, cell death,
and buffering of cytosolic Ca2+ signaling (Hoppe, 2010). How-
ever, subsequent studies have found a multitude of cation chan-
nels that are inhibited by RR derivatives. Thus, off-target effects
of these pharmacological agents may account for the conflicting
results that have fueled the debate as to the true biological func-
tion of thismicrodomain. Further impeding causative experimen-
tation was the unknown genetic identity of the constituents that
comprise the mCa
2+ exchange machinery. Reports from two in-
dependent laboratories identified MCU as the channel-forming
component of the MCU complex and documented its require-
ment for Ca2+ uptake (Baughman et al., 2011; De Stefani et al.,23–34, July 7, 2015 ª2015 The Authors 29
2011). With this discovery, the race was on to generate a loss-of-
function mouse model for comprehensive study to begin to put
into context the vast and often controversial literature regarding
how the dynamic flux of Ca2+ into and out of the mitochondrial
matrix may regulate (patho)physiology. A recent report from
Pan et al. details the phenotype of a Mcu-null mouse generated
using a gene trap strategy (Pan et al., 2013). While the authors
reported a complete loss acute mCa
2+ uptake in various cell
types, the physiological results of the study were quite surpris-
ing. Perhaps most striking was thatMcu ablation had little effect
on cardiac function, structure, or cell death. These results have
prompted the field at large to question the relevance of cardio-
myocyte mCa
2+ flux. Beyond this report, a number of other ques-
tions remained unresolved regarding the impact of mCa
2+
signaling in cardiomyocyte function.
Using a conditional knockout approach to specifically delete
Mcu in cardiomyoyctes in adult mice coupled with in vivo exper-
imental methodologies, we were able to document how acute
mCa
2+ uptake impacts cardiac physiology. We found (1) a reduc-
tion in infarct size assessed both histologically by TTC staining
and TUNEL and biochemically by cTnI levels coupled with in vivo
LV functional data, that all support the notion thatMcu-mediated
mCa
2+ uptake contributes to IR-induced cardiomyocyte cell
death; (2) Mcu KO cells displayed a greater resistance to Ca2+
overload, capable of maintaining Dc following numerous pulses
of Ca2+ in contrast to control cells; and (3) cardiac mitochondria
isolated from Mcu-null cardiomyocytes were completely resis-
tant to swelling. Together these data suggest deletion of Mcu
greatly decreases susceptibility to MPTP activation and thereby
provides protection against necrotic cell death. This result is not
surprising given the numerous reports implicating mCa
2+ load as
a fundamental contributor to MPTP open probability (Rasola and
Bernardi, 2011). Moreover, studies have shown that MPTP inhi-
bition is potently cytoprotective, particularly in I/R injury,
including a clinical trial evaluating the efficacy of cyclosporine-
A (MPTP inhibitor) administration during reperfusion of the
ischemic myocardium (Elrod and Molkentin, 2013; Piot et al.,
2008). It is likely that MPTP inhibition was not the sole protective
mechanism, as decreasing mCa
2+ load is also associated with
decreased reactive oxygen species (ROS) generation during
stress. Supporting this concept, we found a significant decrease
in mitochondrial superoxide levels in Mcu-null cells following
hypoxia/reoxygenation (Figures S1D and S1E).
However, our IR injury results are contradictory to those
recently reported by Pan et al. (2013). Disparities in methodology
likely account for the different results observed here. The previ-
ous study used a gene-trap approach with germline gene inacti-
vation, versus our conditional, cardiomyocyte-specific deletion
in the adult mouse. Therefore, compensatory pathways, induced
by the loss ofMcu during development, may have allowed for the
entry of Ca2+ into thematrix in sufficient quantity, independent of
MCU, to activate mitochondrial-dependent death pathways or
alternatively mitochondrial-independent cell-death pathways
may be upregulated in this mouse. Our finding that germline
deletion of Mcu in our model system was embryonically lethal,
while knocking out Mcu after birth or in adulthood resulted in
no discernable baseline phenotype, supports the notion that sig-
nificant gene changes must have occurred prenatally in their30 Cell Reports 12, 23–34, July 7, 2015 ª2015 The Authorsmodel to support viability. Further, it may be that deletion of
Mcu in other cell types in the heart, such as fibroblasts and endo-
thelial cells, actuallymagnified injury by reducing the mCa
2+-buff-
ering capacity in non-myocytes and thereby masked the protec-
tive effect of loss of Mcu in cardiomyocytes. Supporting this
concept, we found that Mcu-null MEFs displayed an increase
in iCa
2+ transient amplitude following IP3R stimulation (Fig-
ure S1C). Yet another possible reason is the disparity in ischemic
models. The Pan et al. study employed an ex vivo Langendorff
global hypoxia model compared to our in vivo LCA ligation IR
model. There are major differences between these methodolo-
gies, and, while unlikely, perhaps the ex vivo model somehow
lessens the contribution of MCU-dependent Ca2+ uptake in car-
diomyocyte death. Our data do fit with previous reports of ruthe-
nium red derivatives (MCU inhibitors) providing protection
against IR injury (Zhang et al., 2006; Zhao et al., 2013).
The other major difference from the Pan et al. study is that we
found no change in resting mCa
2+ content in Mcu-null cells, in
contrast to their finding of 70% reduction in skeletal muscle
mCa
2+. Our results suggest a MCU-independent mechanism of
mCa
2+ uptake is a significant contributor to homeostatic mCa
2+
levels. We hypothesize that the threshold for MCU-mediated
Ca2+ entry is not reached under homeostatic conditions in adult
cardiomyocytes and that an alternative slowmCa
2+uptakemech-
anism must play a significant role. Direct evidence that MCU-
independent mCa
2+ uptake exists can be seen in our experiment
examining real-time flux in MEFs (Figure 1C). Although we
observed complete loss of the acute and rapid MCU-like mCa
2+
uptake, mCa
2+ content continued to slowly rise with sustained
iCa
2+ load and eventually reached a level equivalent to WT cells.
It is possible that the lower mCa
2+ content previously reported in
Pan et al. can be explained by methodological differences. We
discovered that the slightest perturbation in either extracellular
or iCa
2+ stores in WT cells induced an increase in mCa
2+ loading.
We found that any Ca2+ liberated during our experimental proce-
dure, be it from mitochondrial isolation or SERCA inhibition, was
immediately taken up by WT mitochondria in a Mcu-dependent
fashion. Therefore such a perturbation elevates mCa
2+ content
in control cells andmay lead to a false interpretation of decreased
content in Mcu KO cells. This phenomenon can be seen in
Figure S2C where, in control cells after permeabilization and
addition of thapsigargin, we see a decrease in the Fura ratio prior
to FCCP treatment signifying mCa
2+ uptake, whereas in Mcu-
deleted cellsweobserve a rise in extra-mitochondrial Ca2+ levels.
The addition of the MCU inhibitor, Ru360, and mNCX inhibitor,
CGP37157, prior to experimentation alleviated this problem.
Summarizing the first part of our study, in a clinically relevant
model of IR injury, we provide evidence that Mcu-mediated
Ca2+ uptake is a significant mechanism driving MPTP-mediated
cardiomyocyte cell death and cardiac dysfunction. Further, we
hypothesize that the mCa
2+ exchange system possess a great
deal of plasticity and that alternative uptake mechanisms main-
tain matrix Ca2+ content during homeostasis. A more detailed
examination of this phenomenon in future studies may aid the
discovery of novel exchangers and pathways that account for
the observed ‘‘slow mCa
2+ uptake.’’
The heart is an aerobic organ that must constantly match en-
ergy supply with demand. The contractile function of the normal
heart changes significantly during normal activities. This has led
to the theory that iCa
2+ cycling is integrated withmitochondria on
a beat-to-beat basis to match ATP production with contractile
demand as a real-time regulator of oxidative metabolism (Glancy
and Balaban, 2012). However, our current findings suggest that
rapid MCU-dependent Ca2+ uptake is dispensable for homeo-
static cardiac function, as ablatingMcu had little effect on base-
line function for all measured indices, including little to no change
in LV function, structure, and cellular energetics. We found car-
diomyocyte resting mCa
2+ content to be 200 nM, and we did
not detect appreciable mitochondrial uptake until concentra-
tions of 8 mM were reached (control ACMs displayed only
17% uptake in response to a 10-mM-Ca2+ load). Both of these
values fit nicely within the range of previous studies examining
cardiacMCU function that were recently summarized in eloquent
fashion by Williams et al. (2013). These data also agree with
recent work proposing MICU1 binds MCU to inhibit uptake until
a given threshold or set point of Ca2+ is overcome (Csorda´s et al.,
2013; Mallilankaraman et al., 2012). Since it is assumed global
ECC iCa
2+ cycling does not reach such levels in the homeostatic
beating heart, we hypothesize that a slow MCU-independent
influx mechanism must account for homeostatic maintenance
of matrix Ca2+, aided by balanced mNCX efflux rates. It should
be noted that Ca2+ levels of this magnitude might occur in
discrete microdomains where a sub-population of mitochondria
are tethered in close proximity to SR/T-tubule junctions (Chen
et al., 2012). There are a number of mechanisms that theoreti-
cally could contribute to a slowMCU-independent mCa
2+ uptake
including: mitoRyR, LETM1 (H
+/Ca2+ exchanger), reverse-mode
mNCX, or an as of yet unknown exchanger(s) (Beutner et al.,
2001; Jiang et al., 2009; Palty et al., 2010). Additional evidence
supporting MCU-independent uptake can be seen in a recent
biophysical report describing a second ‘‘RR-insensitive’’
voltage-dependent inward rectifying current (Michels et al.,
2009).We hope that our future experiments will aid the identifica-
tion of this MCU-independent uptake mechanism.
While our data do not support a significant role for the MCU in
basal cardiac physiology, cardiomyocyte-specific deletion did
result in a striking inability to increase contractile function in
response to the classic b-agonist, isoproterenol. Since a study
published by Howell and Duke in 1906, it has been appreciated
that Ca2+ is required for the ‘‘augmenting influence of the sympa-
thetic upon the heart’’ (Howell and Duke, 1906). Our understand-
ing has continued to evolve over the last century, and the various
molecular mechanisms of how bAR signaling regulates changes
in excitation-contraction coupling (ECC) have been defined
(Bers, 2008). Our data extend these pathways to include MCU-
dependent Ca2+ uptake as a mechanism necessary to upregu-
late energetics to support increases in cardiac contractility
during acute sympathetic stress. Catecholamine signaling as oc-
curs with the fight-or-flight response, strenuous exercise, or in
the failing heart, elicits a marked increase in iCa
2+ levels. Specif-
ically, isoproterenol has been shown to dramatically increase
peak iCa
2+ and SR Ca2+ load/release to levels sufficiently
beyond those we show here are required for MCU-dependent
uptake (Curran et al., 2007). This large increase in iCa
2+ is inte-
grated into mitochondria to directly impact cellular energetics
at multiple control points. mCa
2+ increases the activity of threematrix dehydrogenases that are rate-limiting in the tricarboxylic
(TCA) cycle (Denton, 2009). Most notably, matrix Ca2+ has
been shown to indirectly activate pyruvate dehydrogenase
(PDH), which converts pyruvate to acetyl-CoA for entry into the
TCA cycle and as such also links glycolysis withOxPhos (McCor-
mack and England, 1983). We found a marked decrease in PDH
E1 phosphorylation following Iso treatment in control cells, indic-
ative of increased mCa
2+-dependent phosphatase activity and
subsequent PDH enzymatic activation. In contrast, dephosphor-
ylation of PDH was completely lacking in Mcu-KO hearts and
PDH activity during isoproterenol administration was reduced
by50%. In both in vivo and in vitro experiments, we discovered
that loss of Mcu ablated Iso-mediated increases in NADH and
OxPhos capacity. Generally, our metabolic findings are in agree-
ment with Pan et al., which found similar alterations in skeletal
musclemetabolism andwork capacity inMcu/mice subjected
to starvation (Pan et al., 2013). Similarly, our study found no
change in baseline metabolic function or metabolite levels. How-
ever, our finding that HR was not altered inMcu cKO mice does
differ from a recent report by the Anderson group where they re-
ported that an MCU-dominant-negative mouse model lacked
chronotropic responsiveness to b-adrenergic stimulation (Wu
et al., 2015). This may be due to a difference in methodology,
as we did not examine HR with implantable telemeters in
conscious mice void of anesthesia. Overall, our model does sup-
port their hypothesis of MCU-mediated Ca2+ entry playing a sig-
nificant role in the cardiac fight-or-flight response.
In summary, we show that the physiological function of MCU-
mediated Ca2+ uptake in the heart is to augment mitochondrial
energetic signaling to match ATP production with contractile de-
mand during periods of acute adrenergic stress. In addition, our
findings support a pathological role for MCU Ca2+ influx driving
mitochondrial depolarization and cell death during IR injury.
While much work remains to fully elucidate all the molecular con-
stituents of theMCUcomplex and their mechanistic function, our
current study provides a fundamental framework to aid our un-
derstanding of mCa
2+ uptake in health and disease.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Information for detailed experimental
procedures.
Generation of Mcu Conditional Knockout Mice
The gene targeting strategy in embryonic stem cells to generate the Mcu-loxP
mice that we used here is described in Kwong et al. (2015). In short, aMcu con-
ditional knockout mouse by recombinant insertion of a targeting gene
construct containing loxP sites flanking exons 5–6 of the Mcu gene (ch10:
58930544-58911529) in mouse ES cells. Three independent mutant ES cell
lines were confirmed and subjected to morula aggregation, and subsequent
embryos were transplanted into pseudo-pregnant females. Two of the three
mutant ES cell lines produced germline mutant mice, which were crossed
with ROSA26-FLPe knockin mice for removal of the FRT-flanked neomycin
cassette. ResultantMcufl/fl mice were crossed with cardiac specific-Cre trans-
genic mice, aMHC-Cre, and aMHC-MCM, to generate cardiomyocyte-spe-
cific Mcu knockouts. B6.CMV-Cre transgenic mice (Jackson Laboratory,
stock # 006054) were used for germline deletion. For temporal deletion of
Mcu using the MCM model, Mcufl/fl, aMHC-MCM, and Mcufl/fl 3 aMHC-
MCM were injected with i.p. 40 mg/kg/day of tamoxifen for 5 consecutive
days. For all experiments, mice were 10–14 weeks of age. All mutant lines
were maintained on the C57/BL6 background, and all experiments involvingCell Reports 12, 23–34, July 7, 2015 ª2015 The Authors 31
animals were approved by Temple University’s IACUC and followed AAALAC
guidelines.
Western Blot Analysis
All procedures were carried out as previously reported (Elrod et al., 2010).
Isolation of ACMs
ACMs were isolated from ventricular tissue as described previously (Zhou
et al., 2000). All cells were used within 4 hr of isolation.
Evaluation of mCa
2+ Uptake and Content
To evaluate mCa
2+ content, permeabilized ACMswere treated with RU360 and
CGP-37157 to inhibit mCa
2+ flux. Fura2 (Invitrogen) was added to monitor ex-
tra-mitochondrial Ca2+. FCCP was added to uncouple the Dc and release ma-
trix free-Ca2+. To measure mCa
2+ uptake capacity, ACMs were permeabilized
and Fura-FF (Invitrogen) was added to monitor extra-mitochondrial Ca2+. JC-1
(Enzo Life Sciences) was added to monitor Dc. Fluorescence signals for JC-1
and Fura were monitored on a PTI spectrofluorometer. All details are previ-
ously reported (Mallilankaraman et al., 2012).
Mitochondria Isolation and Swelling Assay
Hearts were excised from mice and mitochondria were isolated as reported
(Frezza et al., 2007). For the swelling assay, mitochondria were diluted in
assay buffer, and absorbance (abs) was recorded at 540 nm every 5 s.
500 mM CaCl2 was injected to induce swelling ± 2 mM Cyclosporin A
(CsA) (Elrod et al., 2010).
ACM iCa
2+ Transients
Isolated ACMs were loaded with Fluo-4 AM (Invitrogen) and placed in a 37C
heated chamber on an inverted microscope stage. ACMs were perfused with
Tyrode’s buffer and paced at 0.5 Hz. After baseline recordings, cells were
perfused with Tyrode’s containing 100 nM Iso. Ca2+ transients were analyzed
using Clampfit software.
Mitoplast Patch-Clamp Analysis of MCU Current
Following mitochondrial isolation, mitoplasts were prepared for patch-clamp
studies. IMCU was recorded as previously described in detail (Kirichok et al.,
2004).
Metabolic Assays
Metabolomic analyses were carried out by metabolite profiling of ventricular
tissue by LC-MS/MS as described (Jain et al., 2012). NAD/NADH and
NADP/NADPH ratios were quantified using luminescence assays (Promega).
PDH activity was quantified using a fluorometric assay (Mitosciences).
In vitro experiments of ACMNADHproductionwasmonitored by recording au-
tofluorescence using a spectrofluorometer. A XF96 extracellular flux analyzer
(Seahorse Biosciences) was employed to measure OCR in isolated ACMs.
LV Echocardiography and Hemodynamics
Transthoracic echocardiography of the LV was performed and analyzed on a
Vevo 2100 imaging system as previously reported (Elrod et al., 2007). Invasive
hemodynamic measurements in anesthetized mice was performed using a
pressure catheter inserted into the right carotid artery and guided into the
LV. Right jugular vein catheterization allowed delivery of Iso during recording.
Myocardial IR Injury
LCA ligation and reperfusion was performed as previously described in Gao
et al. (2010). Infarct size was measured as previously reported (Elrod et al.,
2007). Serum was collected from mice after 24 hr R to measure cTnI using
the Life Diagnostics ELISA kit. A TUNEL detection kit (Roche) was used to label
DNA fragmentation in the infarct border zone of fixed heart sections.
MEF Isolation
Embryos were collected fromMcufl/fl mice at E13.5 and MEFs isolated as pre-
viously reported (Baines et al., 2005). MEFs were treated with Ad-Cre or
Ad-bgal for 24 hr. 6-day post-infection cells were used for experiments.32 Cell Reports 12, 23–34, July 7, 2015 ª2015 The AuthorsiCa
2+ and mCa
2+ Flux in MEFs
MEFs were infected with AAV-mitycam to measure mCa
2+ exchange or loaded
with the iCa
2+ indicator, Fluo4-FF. Data were collected every 3 s and analyzed
on Zen software.
Hypoxia/Reoxygenation
MEFs were plated on 35-mm glass plates and, after culturing for 24 hr, loaded
with 5 mMMitoSOX Red (Invitrogen). Cells were placed in ischemic medium for
1 hr, reoxygenated with Tyrode’s buffer, and imaged 5 min later to evaluate
mitochondrial superoxide production.
Statistics
All results are presented as mean ± SEM. Statistical analysis was performed
using Prism 6.0 software (GraphPad). Where appropriate column analyses
were performed using an unpaired, two-tailed t test (for two groups) or one-
way ANOVA with Bonferroni correction (for groups of three or more). For
grouped analyses, either multiple unpaired t test with correction for multiple
comparisons using the Holm-Sidak method or, where appropriate, two-way
ANOVA with Tukey post hoc analysis was performed. p values <0.05 were
considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.06.017.
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